



MARZIA CERRATO

Nationality: Italian **Date of birth:** 15/08/1987 **Place of birth:** Turin, Italy

Phone number: (+39) 3332603174 **Email address:** mrz.cerrato@gmail.com

Home: Via Abate Pietro Chanoux 12/13, 10142 Turin (Italy)

WORK EXPERIENCE

Radioterapia U, A.O.U. Città della Salute e della Scienza di Torino – Turin, Italy

City: Turin | Country: Italy

Radiation Oncologist

[15/06/2023 – Current]

EDUCATION AND TRAINING

ESTRO (European Society Radiation Oncology) member

[01/01/2019 – Current]

AIRO (Associazione Italiana di Radioterapia ed Oncologia Clinica) member

[01/01/2019 – Current]

Postgraduate Degree in Radiotherapy

University of Turin [01/11/2018 – 03/11/2022]

City: Torino | Country: Italy | Final grade: 70 cum laude | Thesis: Association between dose-volume parameters of cardiac substructures and cardiac toxicity in patients with non-small cell lung cancer treated with radical radiotherapy: interim analysis of the LUNG-HEART Study.

- Clinical and therapeutic management of major oncological diseases.
- Research activities on cranial and extracranial Stereotactic Ablative Radiotherapy (SRS- SABR).
- Research activities focused on lung cancer.
- Research activities on cardiotoxicity related to treatments for stage I-III NSCLC.
- Research activities on radiotherapy treatment in lymphoproliferative diseases.
- Clinical and research activities on Stereotactic Arrhythmia Radioablation (STAR).
- Special techniques: TSEBI, TMI/TMLI, STAR

Single-Cycle Master's Degree in Medicine and Surgery

University of Turin [01/10/2007 – 31/10/2017]

City: Turin | Country: Italy | Final grade: 110 cum laude. Thesis deemed worthy of publication.

LANGUAGE SKILLS

Mother tongue(s): Italian

Other language(s):

English

LISTENING C1 READING C1 WRITING C1

SPOKEN PRODUCTION B2 SPOKEN INTERACTION B2

Levels: A1 and A2: Basic user; B1 and B2: Independent user; C1 and C2: Proficient user

PERSONAL SKILLS

Individual strengths

- Soft skills
- Strong communication abilities
- Teamwork and collaboration
- Problem-solving attitude
- Adaptability and flexibility
- Empathy

COMPUTER SKILLS

Digital skills

- Microsoft Office Suite (Word, Excel, PowerPoint)
- Basic data analysis and interpretation (Excel or statistical tools like SPSS or R)

PUBLICATIONS

[2024]

Radiotherapy in the Conditioning Regimen of Allogeneic Hematopoietic Stem Cell Transplant: Rational, Clinical Implications and Technical Aspects

Authors: Levis M., Cerrato M., Cuffini E.M., Casale C., Ricardi U. | Journal Name: Comprehensive Hematology and Stem Cell Research | Volume, Issue and Pages: vol. 5, pp. 304–334. | Publisher: Elsevier

ISBN: 9780443157172 <https://dx.doi.org/10.1016/B978-0-443-15717-2.00112-8>

[2022]

A case report of long-term successful stereotactic arrhythmia radioablation in a cardiac contractility modulation device carrier with giant left atrium, including a detailed dosimetric analysis

Levis M, Dusi V, Magnano M, Cerrato M, Gallio E, Depaoli A, Ferraris F, De Ferrari GM, Ricardi U, Anselmino M. A case report of long-term successful stereotactic arrhythmia radioablation in a cardiac contractility modulation device carrier with giant left atrium, including a detailed dosimetric analysis. Front Cardiovasc Med. 2022 Aug 22;9:934686. doi: 10.3389/fcvm.2022.934686. PMID: 36072883; PMCID: PMC9441661.

[2022]

Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC

Badellino S, Levis M, Cuffini EM, Cerrato M, Orlandi E, Chiovatero I, Aprile A, Gastino A, Cavallin C, Iorio GC, Parise R, Mantovani C, Ricardi U. Role of Radiosurgery and Stereotactic Ablative Radiotherapy for Oligometastatic Non-Oncogene Addicted NSCLC. Cancers (Basel). 2022 Mar 12;14(6):1465. doi: 10.3390/cancers14061465. PMID: 35326616; PMCID: PMC8946847.

[2021]

Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions

Mantovani C, Gastino A, Cerrato M, Badellino S, Ricardi U, Levis M. Modern Radiation Therapy for the Management of Brain Metastases From Non-Small Cell Lung Cancer: Current Approaches and Future Directions. Front Oncol. 2021 Nov 2;11:772789. doi: 10.3389/fonc.2021.772789. PMID: 34796118; PMCID: PMC8593461.

[2021]

Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas

Cerrato M, Orlandi E, Vella A, Bartoncini S, Iorio GC, Bongiovanni D, Capriotti F, Boccomini C, Vassallo F, Cavallin C, De Luca V, Giglioli FR, Ricardi U, Levis M. Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas. *Br J Radiol*. 2021 Jul 1;94(1123):20210012. doi: 10.1259/bjr.20210012. Epub 2021 Jun 16. PMID: 34111959; PMCID: PMC8248200.

[2021]

Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration Associated with Merkel Cell Carcinoma with Unknown Primary: A Case Report

Agostini A, Merli M, Avallone G, Burzi L, Mastorino L, Parisi M, Bertuzzo D, Ferrero B, Cerrato M, Badellino S, Molinaro L, Lopiano L, Ribero S, Quaglino P. Lambert-Eaton Myasthenic Syndrome and Paraneoplastic Cerebellar Degeneration Associated with Merkel Cell Carcinoma with Unknown Primary: A Case Report. *Acta Derm Venereol*. 2021 May 10;101(5):adv00452. doi: 10.2340/00015555-3798. PMID: 33846760; PMCID: PMC9367044.

[2021]

Cardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy - Old Foes Still Threatening Cancer Survivors?

Maraldo MV, Andreis A, Iamundo de Cumis I, Cerrato M, Vella A, Ricardi U, Levis M. Cardiometabolic Risk, Part 1: Chemotherapy and Radiotherapy - Old Foes Still Threatening Cancer Survivors? *Front Horm Res*. 2021;54:115-129. doi: 10.1159/000513921. Epub 2021 Feb 8. PMID: 33556955.

[2020]

Safety of lung stereotactic ablative radiotherapy for the functioning of cardiac implantable electronic devices

Levis M, Andreis A, Badellino S, Budano C, Caivano D, Cerrato M, Orlandi E, Bissolino A, Angelico G, Cavallin C, Giglioli FR, De Ferrari GM, Ricardi U. Safety of lung stereotactic ablative radiotherapy for the functioning of cardiac implantable electronic devices. *Radiother Oncol*. 2021 Mar;156:193-198. doi: 10.1016/j.radonc.2020.12.029. Epub 2020 Dec 30. PMID: 33387584.

CLINICAL RESEARCH PROJECTS (INVESTIGATOR)

[01/07/2019 – Current]

LUNG-HEART Study

Relationship between heart substructures dose-volume parameters and survival after radiotherapy in Non Small Cell Lung Cancer patients. LUNG-HEART Study

CLINICAL RESEARCH PROJECTS (CO-INVESTIGATOR)

[01/02/2024 – Current]

Synchrony® Radixact® Study

Synchrony® Radixact® tumor tracking system in stereotactic ablative radiotherapy treatment with helical TomoTherapy.

[30/09/2024 – Current]

OligoRARE

Stereotactic body radiotherapy in addition to standard of care treatment in patients with rare oligometastatic cancers (OligoRARE): a randomized, phase 3, open-label trial

[26/03/2025 – 29/03/2025]

137MO: Impact of cardiac substructure dose on cardiotoxicity and overall survival (OS) in early-stage non-small cell lung cancer (ES-NSCLC) patients receiving stereotactic ablative body radiotherapy (SABR): Data from the interim analysis of the LUNG HEART study

M. Cerrato, S. Badellino, G. Petruzzellis, A. Celisami, M. Levis, U. Ricardi. Mini-Oral presentation. Journal of Thoracic Oncology, Volume 20, Issue 3, S100. DOI:10.1016/S1556-0864(25)00333-8
ELCC 2025, Paris

[21/06/2024 – 23/06/2024]

Stereotactic ablative radiotherapy (SABR) in early-stage Non-Small Cell Lung Cancer: results on 20 years of experience.

M. Cerrato, S. Badellino, I. Bonavero, E. M. Cuffini, F. Catena, F. Menegatti, M. Levis, U. Ricardi. Oral Communication. 34th AIRO National Congress – AIRO 2024, Curing to Heal, Milan

[03/05/2024 – 07/05/2024]

SABR prior to liver transplantation in HCC patients: a 10 years' experience

M. Cerrato, S. Leardi, R. Parise, B. Lo Zito, V. Chiofalo, D. Patrono, F. Colli, R. Romagnoli, P. Carucci, S. Gaia, E. Rolle, S. Bartoncini, G. C. Iorio, S. Badellino, P. Ancelliero, M. Levis, U. Ricardi. Mini-Oral presentation, Radiotherapy and Oncology (2024) 194:S2277–S2281. doi: 10.1016/S0167-8140(24)03096-2.
ESTRO 2024, Glasgow

[03/05/2024 – 07/05/2024]

SABR for ES-NSCLC in very elderly (≥80 years old) patients: results on 18 years of experience

M. Cerrato, F. Menegatti, S. Badellino, E. M. Cuffini, B. Lo Zito, I. Bonavero, S. Leardi, C. Casale, R. Parise, G. Novero, M. Levis, U. Ricardi. Poster Online. Radiotherapy and Oncology (2024) 194:S1792–S1795. doi: 10.1016/S0167-8140(24)03043-3
ESTRO 2024, Glasgow

[12/05/2023 – 16/05/2023]

Dose to heart substructures is associated with grade > 3 cardiac events after SABR in stage I-II NSCLC.

Cerrato M, Menegatti F, Bonavero I, Casale C, Grossi C, Badellino S, Parise R, Ricardi U, Levis M. Mini- Oral - MO-0643. Radiotherapy and Oncology (2023) 182:S535–S536. doi: 10.1016/S0167-8140(23)08427-X.
ESTRO 2023, Vienna

[12/05/2023 – 16/05/2023]

Dosimetric and clinical aspects of lung SABR delivered with Synchrony® tracking on Tomotherapy.

Cerrato M, Gallio E, Menegatti F, Bonavero I, Grossi C, Casale C, Brossa P, Badellino S, Giglioli FR, Parise R, et al. Poster Discussion - PD-0982. Radiotherapy and Oncology (2023) 182:S830. doi: 10.1016/S0167-8140(23)09055-2.
ESTRO 2023, Vienna

[12/05/2023 – 16/05/2023]

Initial clinical experience with ITV-free Lung SABR using Synchrony tracking on Radixact Tomotherapy.

Menegatti F, Cerrato M, Grossi C, Gallio E, Bonavero I, Casale C, Brossa P, Badellino S, Giglioli FR, Parise R. Poster Online - PO-2001. Radiotherapy and Oncology (2023) 182:S1773–S1775. doi: 10.1016/S0167-8140(23)66916-6.
ESTRO 2023, Vienna

[12/05/2023 – 16/05/2023]

Long-term outcomes for NSCLC patients with brain metastases treated with SRS or SRT.

Chiovatero I, Gastino A, Bonavero I, De Giorgi G, Cuffini E, Casale C, Cerrato M, Blasi L, Badellino S, Mantovani C. Poster Online - PO-1130 Radiotherapy and Oncology (2023) 182:S903-S904. doi: 10.1016/S0167-8140(23)09127-2.

ESTRO 2023, Vienna

[06/05/2022 – 10/05/2022]

Early adjuvant RT as a predictor of improved outcomes in patients with grade II and III meningiomas

E.M. Cuffini, C. Casale, C. Mantovani, A. Gastino, B. Lo Zito, L. Blasi, D. Bongiovanni, E. Orlandi, M. Cerrato, A. Vella, S. Leardi, V. Chiofalo, C. Cavallin, G.C. Iorio, U. Ricardi, M. Levis. Oral Communication. Radiotherapy and Oncology, Volume 170, Supp 1, ISSN 0167-8140, S816-S817, OC- 0925, doi: 10.1016/S0167-8140(22)02705-0.

ESTRO 2022, Copenhagen

[06/05/2022 – 10/05/2022]

Cardiac toxicity predicts mortality in NSCLC patients: interim analysis of the LUNG-HEART Study

M. Cerrato, S. Badellino, F. Menegatti, I. Bonavero, C. Grossi, B. Lo Zito, E. Orlandi, A. Gastino, E.M. Cuffini, L. Blasi, C. Mantovani, R. Parise, U. Ricardi, M. Levis. Poster Discussion. Radiotherapy and Oncology, Volume 170, Supp 1, ISSN 0167-8140, S607- 5608, PD- 0672, doi: 10.1016/S0167-8140(22)02919-X.

ESTRO 2022, Copenhagen

[27/08/2021 – 31/08/2021]

Low-dose radiotherapy (4 Gy) in the treatment of marginal zone B- cell lymphomas

M. Cerrato, E. Orlandi, A. Vella, S. Bartoncini, G.C. Iorio, D. Bongiovanni, F. Capriotti, C. Boccomini, F. Vassallo, C. Cavallin, V. De Luca, F.R. Giglioli, U. Ricardi, M. Levis. Poster Online. Radiotherapy and Oncology, Volume 161, Supp 1, ISSN 0167-8140, 5898-5899, PO-1080, doi: 10.1016/S0167-8140(21)07531-9.

ESTRO 2021, Madrid

[27/08/2021 – 31/08/2021]

Effects of SRS in patients affected with brain metastases from NSCLC: a single institution report

I. Chiovatero, C. Mantovani, A. Vella, G.C. Iorio, E. Orlandi, M. Cerrato, C. Cavallin, S. Badellino, A. Gastino, E.M. Cuffini, M. Levis, U. Ricardi. Poster Online. Radiotherapy and Oncology, Volume 161, Supp 1, ISSN 0167-8140, 5860-5862, PO-1032, doi: 10.1016/S0167-8140(21)07483-1.

ESTRO 2021, Madrid

[16/06/2021 – 16/06/2021]

Do computed tomography radiomic features change according to toxicity grade for patients with early stage lung cancer underwent SBRT?

E. Gallio, C. Cavallin, M. Cerrato, D. Caivano, S. Badellino, O. Rampado, F.R. Giglioli, R. Ropolo, U. Ricardi. Poster Online. Physica Medica, Volume 92, S 157, P-32, doi: 10.1016/S1120-1797(22)00334-9.

European Congress of Medical Physics (ECMP) and National Congress AIFM.

[28/11/2020 – 01/12/2020]

Lung stereotactic ablative radiotherapy in elderly patients: safety and efficacy.

C. Cavallin, S. Badellino, M. Cerrato, D. Caivano, I. Chiovatero, A. Vella, J. Di Muzio, C. Mantovani, M. Levis, U. Ricardi. Poster Online. Radiotherapy and Oncology, Volume 152, Supp 1, ISSN 0167-8140, 5669, PO-1271, doi : 10.1016/S0167-8140(21)01289-5.

ESTRO 2020

[28/11/2020 – 01/12/2020]

Risk of brain radionecrosis after radiosurgery in oligometastatic patients

I. Chiovatero, C. Mantovani, G.C. Iorio, C. Cavallin, A. Vella, E. Orlandi, M. Cerrato, S. Badellino, D. Caivano, M. Levis, V. De Luca, U. Ricardi. Poster Online. Radiotherapy and Oncology, Volume 152, Supp 1, ISSN 0167-8140, S481, PO-0899, doi: 10.1016/S0167-8140(21)00916-6.

ESTRO 2020.

[16/11/2019 – 16/11/2019]

Relationship between heart substructures dose-volume parameters and survival after radiotherapy in Non Small Cell Lung Cancer patients. Lung-Heart

M.Cerrato, C.Cavallin, A.Vella, I.Chiovatero, S.Badellino, D.Caivano, C.Mantovani, M.Levis, U.Ricardi. Oral Communication.

Conference of the Regional AIRO Group Liguria – Piedmont – Aosta Valley (Santa Margherita Ligure).

Non-Small Cell Lung Cancer: Focus on New Technologies and Integration with Immunotherapy.

[16/11/2019 – 16/11/2019]

Outcomes of Radiosurgery in Non Small Cell Lung Cancer (NSCLC) oligometastatic patients

I.Chiovatero, A.Vella, G.C.Iorio, E.Orlandi, M.Cerrato, C.Cavallin, C.Mantovani, M.Levis, S.Badellino, D.Caivano, U.Ricardi.

Oral Communication.

Conference of the Regional AIRO Group Liguria – Piedmont – Aosta Valley (Santa Margherita Ligure).

Non-Small Cell Lung Cancer: Focus on New Technologies and Integration with Immunotherapy.

CONFERENCES AND SEMINARS (PRESENTER)

[26/03/2025 – 29/03/2025]

137MO: Impact of cardiac substructure dose on cardiotoxicity and overall survival (OS) in early-stage non-small cell lung cancer (ES-NSCLC) patients receiving stereotactic ablative body radiotherapy (SABR): Data from the interim analysis of the LUNG HEART study

Mini-Oral presentation. European Lung Cancer Congress - ELCC 2025, Paris

[27/02/2025 – 28/02/2025]

NSCLC stage III

Multidisciplinary Approach in Clinical Practice. From Borderline Cases to the Frail Patient: The Radiation Oncologist's Perspective.

Turin

[14/12/2024]

Management of Oligometastatic Disease: Indications in Lung Cancer.

Evidence-Based Radiotherapy in the Evolving Technological, Therapeutic, and Diagnostic Landscape.

Conference of the Regional AIRO Group – Liguria, Piedmont, Aosta Valley (Verduno Hospital).

[21/06/2024 – 23/06/2024]

Stereotactic ablative radiotherapy (SABR) in early-stage Non-Small Cell Lung Cancer: results on 20 years of experience.

Oral Communication. 34th AIRO National Congress – AIRO 2024 , Curing to Heal, Milan

[03/05/2024 – 07/05/2024]

SABR prior to liver transplantation in HCC patients: a 10 years' experience

Mini Oral. European Society for Radiotherapy and Oncology - ESTRO 2023, Glasgow.

[29/02/2024 – 01/03/2024]

NSCLC stage III

Cardiotoxicity

Turin

[05/10/2023]

Unresectable Lung Tumor

Practice Session: Tumor Volume and OARs Delineation in Radiotherapy Treatment Planning

Turin

[04/06/2023 – 08/06/2023]

Estro Course IMRT/VMAT and other highly conformal techniques in clinical practice

SBRT for lung tumors: respiratory motion management and 4D-CBCT

ESTRO course 2023, Torino

[12/05/2023 – 16/05/2023]

Dose to heart substructures is associated with grade > 3 cardiac events after SABR in stage I-II NSCLC.

Mini Oral. European Society for Radiotherapy and Oncology - ESTRO 2023, Vienna.

[12/05/2023 – 16/05/2023]

Dosimetric and clinical aspects of lung SABR delivered with Synchrony® tracking on Tomotherapy.

Poster Discussion. European Society for Radiotherapy and Oncology - ESTRO 2023, Vienna.

[06/05/2022 – 10/05/2022]

Cardiac toxicity predicts mortality in NSCLC patients: interim analysis of the LUNG-HEART Study

Poster Discussion. European Society for Radiotherapy and Oncology - ESTRO 2022, Copenhagen.

[16/11/2019 – 16/11/2019]

Relationship between heart substructures dose-volume parameters and survival after radiotherapy in Non Small Cell Lung Cancer patients. Lung-Heart

Oral Communication. Non-Small Cell Lung Cancer: Focus on New Technologies and Integration with Immunotherapy.

Conference of the Regional AIRO Group Liguria – Piedmont – Aosta Valley (Santa Margherita Ligure).

I authorize the processing of my personal data contained in my CV in accordance with Article 13 of Legislative Decree No. 196 of June 30, 2003 - 'Personal Data Protection Code' - and Article 13 of EU Regulation 2016/679 - 'General Data Protection Regulation (GDPR)'.

Turin, 11/06/2025

A handwritten signature in red ink, appearing to read 'Marzia Cerrato', is written over a light yellow rectangular background.

MARZIA CERRATO

Alla cortese attenzione del Coordinatore del Gruppo di Studio Oncologia toracica e del Direttivo AIRO, con la presente desidero sottoporre la mia candidatura alla posizione di Consigliere del Gruppo di Studio "Polmone" di AIRO, motivata da un interesse scientifico e clinico consolidato nell'ambito delle neoplasie toraciche e da una forte volontà di contribuire in maniera attiva e propositiva alla crescita e all'organizzazione strategica delle attività del gruppo.

Nel corso della mia attività in radioterapia oncologica ho sviluppato un interesse specifico nella gestione integrata dei tumori polmonari. Ho partecipato a progetti di ricerca e protocolli clinici istituzionali, in particolare nell'ambito del potenziale impatto della radioterapia a scopo radicale sullo sviluppo di cardiotossicità.

Considerato il vasto interesse della comunità radioterapica, riterrei utile la realizzazione di una revisione sistematica della letteratura per individuare i dose constraints più aggiornati nei trattamenti toracici con frazionamenti ipofrazionati e nelle reirradiazioni polmonari, due ambiti di crescente rilevanza clinica. L'obiettivo è fornire uno strumento pratico, condiviso e aggiornato per la pianificazione clinica quotidiana e per la standardizzazione dei trattamenti nei diversi centri.

Resto a disposizione per fornire ulteriori informazioni utili alla valutazione della mia candidatura.

Cordiali saluti,
Marzia Cerrato

Città della Salute e della Scienza di Torino